nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—CTSG—blood plasma—hepatitis B	0.0258	0.159	CbGeAlD
Bortezomib—CTSG—blood—hepatitis B	0.00944	0.0581	CbGeAlD
Bortezomib—PSMD1—blood—hepatitis B	0.00761	0.0468	CbGeAlD
Bortezomib—PSMA1—liver—hepatitis B	0.00709	0.0436	CbGeAlD
Bortezomib—PSMD2—blood—hepatitis B	0.00674	0.0415	CbGeAlD
Bortezomib—PSMB8—blood—hepatitis B	0.0067	0.0412	CbGeAlD
Bortezomib—PSMD1—liver—hepatitis B	0.00595	0.0366	CbGeAlD
Bortezomib—PSMB5—blood—hepatitis B	0.00592	0.0364	CbGeAlD
Bortezomib—PSMD2—liver—hepatitis B	0.00527	0.0325	CbGeAlD
Bortezomib—PSMB8—liver—hepatitis B	0.00524	0.0323	CbGeAlD
Bortezomib—PSMB1—blood—hepatitis B	0.00517	0.0318	CbGeAlD
Bortezomib—PSMB2—blood—hepatitis B	0.00505	0.0311	CbGeAlD
Bortezomib—CYP2C19—blood plasma—hepatitis B	0.00503	0.031	CbGeAlD
Bortezomib—PSMB5—liver—hepatitis B	0.00463	0.0285	CbGeAlD
Bortezomib—CYP2C8—blood plasma—hepatitis B	0.00439	0.027	CbGeAlD
Bortezomib—SLC31A1—blood—hepatitis B	0.00437	0.0269	CbGeAlD
Bortezomib—CYP1A2—blood plasma—hepatitis B	0.00411	0.0253	CbGeAlD
Bortezomib—PSMB1—liver—hepatitis B	0.00404	0.0249	CbGeAlD
Bortezomib—PSMB2—liver—hepatitis B	0.00395	0.0243	CbGeAlD
Bortezomib—CYP2C9—blood plasma—hepatitis B	0.0039	0.024	CbGeAlD
Bortezomib—PTGS1—blood plasma—hepatitis B	0.00356	0.0219	CbGeAlD
Bortezomib—SLC31A1—liver—hepatitis B	0.00342	0.021	CbGeAlD
Bortezomib—CYP3A4—blood plasma—hepatitis B	0.00297	0.0183	CbGeAlD
Bortezomib—CYP2D6—blood plasma—hepatitis B	0.00292	0.018	CbGeAlD
Bortezomib—Musculoskeletal pain—Telbivudine—hepatitis B	0.00292	0.00632	CcSEcCtD
Bortezomib—Gingival bleeding—Lamivudine—hepatitis B	0.00287	0.0062	CcSEcCtD
Bortezomib—Hepatic failure—Entecavir—hepatitis B	0.00284	0.00614	CcSEcCtD
Bortezomib—Hepatic failure—Adefovir Dipivoxil—hepatitis B	0.00277	0.00599	CcSEcCtD
Bortezomib—Renal impairment—Adefovir Dipivoxil—hepatitis B	0.00261	0.00566	CcSEcCtD
Bortezomib—Respiratory tract infection—Lamivudine—hepatitis B	0.00259	0.0056	CcSEcCtD
Bortezomib—Hypoxia—Lamivudine—hepatitis B	0.00256	0.00554	CcSEcCtD
Bortezomib—Sepsis—Telbivudine—hepatitis B	0.0025	0.00542	CcSEcCtD
Bortezomib—Abdominal pain upper—Entecavir—hepatitis B	0.00233	0.00504	CcSEcCtD
Bortezomib—Myopathy—Lamivudine—hepatitis B	0.00232	0.00502	CcSEcCtD
Bortezomib—Hepatomegaly—Lamivudine—hepatitis B	0.0023	0.00497	CcSEcCtD
Bortezomib—Renal impairment—Telbivudine—hepatitis B	0.0022	0.00476	CcSEcCtD
Bortezomib—Pancreatitis—Entecavir—hepatitis B	0.00216	0.00468	CcSEcCtD
Bortezomib—Pancreatitis—Adefovir Dipivoxil—hepatitis B	0.00211	0.00456	CcSEcCtD
Bortezomib—Pain in extremity—Telbivudine—hepatitis B	0.0021	0.00453	CcSEcCtD
Bortezomib—Migraine—Telbivudine—hepatitis B	0.00206	0.00446	CcSEcCtD
Bortezomib—Neutropenia—Entecavir—hepatitis B	0.00206	0.00446	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Entecavir—hepatitis B	0.00205	0.00443	CcSEcCtD
Bortezomib—Rhinorrhoea—Lamivudine—hepatitis B	0.00201	0.00434	CcSEcCtD
Bortezomib—Hyperglycaemia—Entecavir—hepatitis B	0.00199	0.0043	CcSEcCtD
Bortezomib—Dysphonia—Lamivudine—hepatitis B	0.00198	0.00428	CcSEcCtD
Bortezomib—Blood disorder—Lamivudine—hepatitis B	0.00195	0.00421	CcSEcCtD
Bortezomib—Weight decreased—Adefovir Dipivoxil—hepatitis B	0.00195	0.00421	CcSEcCtD
Bortezomib—Acne—Lamivudine—hepatitis B	0.00193	0.00418	CcSEcCtD
Bortezomib—Renal failure—Entecavir—hepatitis B	0.00193	0.00418	CcSEcCtD
Bortezomib—Abdominal pain upper—Telbivudine—hepatitis B	0.00191	0.00414	CcSEcCtD
Bortezomib—Cramp muscle—Telbivudine—hepatitis B	0.00189	0.00408	CcSEcCtD
Bortezomib—Renal failure—Adefovir Dipivoxil—hepatitis B	0.00189	0.00408	CcSEcCtD
Bortezomib—Haematuria—Entecavir—hepatitis B	0.00187	0.00405	CcSEcCtD
Bortezomib—Nasopharyngitis—Telbivudine—hepatitis B	0.00187	0.00405	CcSEcCtD
Bortezomib—Hepatobiliary disease—Entecavir—hepatitis B	0.00186	0.00402	CcSEcCtD
Bortezomib—Gastritis—Telbivudine—hepatitis B	0.00185	0.00401	CcSEcCtD
Bortezomib—Muscular weakness—Telbivudine—hepatitis B	0.00185	0.004	CcSEcCtD
Bortezomib—CYP2C19—blood—hepatitis B	0.00184	0.0113	CbGeAlD
Bortezomib—Rhabdomyolysis—Lamivudine—hepatitis B	0.00184	0.00398	CcSEcCtD
Bortezomib—Haematuria—Adefovir Dipivoxil—hepatitis B	0.00183	0.00396	CcSEcCtD
Bortezomib—Abdominal distension—Telbivudine—hepatitis B	0.00182	0.00394	CcSEcCtD
Bortezomib—Hepatobiliary disease—Adefovir Dipivoxil—hepatitis B	0.00181	0.00392	CcSEcCtD
Bortezomib—Influenza—Telbivudine—hepatitis B	0.00181	0.00392	CcSEcCtD
Bortezomib—Bone disorder—Lamivudine—hepatitis B	0.0018	0.0039	CcSEcCtD
Bortezomib—Viral infection—Lamivudine—hepatitis B	0.0018	0.0039	CcSEcCtD
Bortezomib—Sinusitis—Adefovir Dipivoxil—hepatitis B	0.0018	0.00389	CcSEcCtD
Bortezomib—Oropharyngeal pain—Lamivudine—hepatitis B	0.00179	0.00387	CcSEcCtD
Bortezomib—Hepatitis—Entecavir—hepatitis B	0.00176	0.00382	CcSEcCtD
Bortezomib—Oedema peripheral—Entecavir—hepatitis B	0.00174	0.00376	CcSEcCtD
Bortezomib—Abdominal discomfort—Telbivudine—hepatitis B	0.00174	0.00376	CcSEcCtD
Bortezomib—Hepatitis—Adefovir Dipivoxil—hepatitis B	0.00172	0.00372	CcSEcCtD
Bortezomib—Hearing impaired—Lamivudine—hepatitis B	0.00171	0.0037	CcSEcCtD
Bortezomib—Urinary tract disorder—Adefovir Dipivoxil—hepatitis B	0.0017	0.00368	CcSEcCtD
Bortezomib—Neutropenia—Telbivudine—hepatitis B	0.00169	0.00366	CcSEcCtD
Bortezomib—Connective tissue disorder—Adefovir Dipivoxil—hepatitis B	0.00169	0.00366	CcSEcCtD
Bortezomib—Urethral disorder—Adefovir Dipivoxil—hepatitis B	0.00169	0.00365	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Telbivudine—hepatitis B	0.00168	0.00364	CcSEcCtD
Bortezomib—Inflammation—Lamivudine—hepatitis B	0.00168	0.00363	CcSEcCtD
Bortezomib—Vasculitis—Lamivudine—hepatitis B	0.00167	0.00361	CcSEcCtD
Bortezomib—Muscle twitching—Lamivudine—hepatitis B	0.00166	0.00358	CcSEcCtD
Bortezomib—Musculoskeletal pain—Lamivudine—hepatitis B	0.00165	0.00356	CcSEcCtD
Bortezomib—CYP2C8—blood—hepatitis B	0.00161	0.0099	CbGeAlD
Bortezomib—Immune system disorder—Entecavir—hepatitis B	0.00159	0.00345	CcSEcCtD
Bortezomib—Renal failure—Telbivudine—hepatitis B	0.00159	0.00343	CcSEcCtD
Bortezomib—Neuropathy peripheral—Telbivudine—hepatitis B	0.00158	0.00342	CcSEcCtD
Bortezomib—Wheezing—Lamivudine—hepatitis B	0.00158	0.00342	CcSEcCtD
Bortezomib—Mental disorder—Entecavir—hepatitis B	0.00155	0.00334	CcSEcCtD
Bortezomib—Malnutrition—Entecavir—hepatitis B	0.00154	0.00332	CcSEcCtD
Bortezomib—Photophobia—Lamivudine—hepatitis B	0.00153	0.0033	CcSEcCtD
Bortezomib—Neuropathy—Lamivudine—hepatitis B	0.00153	0.0033	CcSEcCtD
Bortezomib—Hepatobiliary disease—Telbivudine—hepatitis B	0.00153	0.0033	CcSEcCtD
Bortezomib—CYP1A2—blood—hepatitis B	0.0015	0.00926	CbGeAlD
Bortezomib—Malnutrition—Adefovir Dipivoxil—hepatitis B	0.0015	0.00324	CcSEcCtD
Bortezomib—CYP1A1—blood—hepatitis B	0.00148	0.00914	CbGeAlD
Bortezomib—Flatulence—Adefovir Dipivoxil—hepatitis B	0.00148	0.00319	CcSEcCtD
Bortezomib—Mouth ulceration—Lamivudine—hepatitis B	0.00147	0.00318	CcSEcCtD
Bortezomib—Back pain—Adefovir Dipivoxil—hepatitis B	0.00145	0.00314	CcSEcCtD
Bortezomib—Hepatitis—Telbivudine—hepatitis B	0.00145	0.00314	CcSEcCtD
Bortezomib—Hypoaesthesia—Telbivudine—hepatitis B	0.00144	0.00312	CcSEcCtD
Bortezomib—CYP2C19—liver—hepatitis B	0.00144	0.00887	CbGeAlD
Bortezomib—CYP2C9—blood—hepatitis B	0.00143	0.00879	CbGeAlD
Bortezomib—Connective tissue disorder—Telbivudine—hepatitis B	0.00142	0.00308	CcSEcCtD
Bortezomib—Sepsis—Lamivudine—hepatitis B	0.00141	0.00305	CcSEcCtD
Bortezomib—Anaemia—Adefovir Dipivoxil—hepatitis B	0.00139	0.003	CcSEcCtD
Bortezomib—Lymphadenopathy—Lamivudine—hepatitis B	0.00138	0.00299	CcSEcCtD
Bortezomib—Leukopenia—Entecavir—hepatitis B	0.00137	0.00297	CcSEcCtD
Bortezomib—Phlebitis—Lamivudine—hepatitis B	0.00137	0.00297	CcSEcCtD
Bortezomib—Sleep disorder—Lamivudine—hepatitis B	0.00136	0.00295	CcSEcCtD
Bortezomib—Gastroenteritis—Lamivudine—hepatitis B	0.00133	0.00288	CcSEcCtD
Bortezomib—Deafness—Lamivudine—hepatitis B	0.00132	0.00286	CcSEcCtD
Bortezomib—Cough—Adefovir Dipivoxil—hepatitis B	0.00131	0.00283	CcSEcCtD
Bortezomib—Mediastinal disorder—Telbivudine—hepatitis B	0.00131	0.00283	CcSEcCtD
Bortezomib—PTGS1—blood—hepatitis B	0.0013	0.00803	CbGeAlD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Entecavir—hepatitis B	0.0013	0.00281	CcSEcCtD
Bortezomib—Myalgia—Adefovir Dipivoxil—hepatitis B	0.00128	0.00276	CcSEcCtD
Bortezomib—Chest pain—Adefovir Dipivoxil—hepatitis B	0.00128	0.00276	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Adefovir Dipivoxil—hepatitis B	0.00127	0.00274	CcSEcCtD
Bortezomib—Malnutrition—Telbivudine—hepatitis B	0.00126	0.00273	CcSEcCtD
Bortezomib—CYP2C8—liver—hepatitis B	0.00126	0.00774	CbGeAlD
Bortezomib—Anaphylactic shock—Entecavir—hepatitis B	0.00125	0.00271	CcSEcCtD
Bortezomib—Infection—Entecavir—hepatitis B	0.00125	0.00269	CcSEcCtD
Bortezomib—Renal impairment—Lamivudine—hepatitis B	0.00124	0.00268	CcSEcCtD
Bortezomib—Thirst—Lamivudine—hepatitis B	0.00124	0.00268	CcSEcCtD
Bortezomib—Dysgeusia—Telbivudine—hepatitis B	0.00124	0.00267	CcSEcCtD
Bortezomib—Nervous system disorder—Entecavir—hepatitis B	0.00123	0.00266	CcSEcCtD
Bortezomib—Back pain—Telbivudine—hepatitis B	0.00122	0.00264	CcSEcCtD
Bortezomib—Skin disorder—Entecavir—hepatitis B	0.00122	0.00263	CcSEcCtD
Bortezomib—Muscle spasms—Telbivudine—hepatitis B	0.00121	0.00262	CcSEcCtD
Bortezomib—Nervous system disorder—Adefovir Dipivoxil—hepatitis B	0.0012	0.00259	CcSEcCtD
Bortezomib—Thrombocytopenia—Adefovir Dipivoxil—hepatitis B	0.0012	0.00259	CcSEcCtD
Bortezomib—Skin disorder—Adefovir Dipivoxil—hepatitis B	0.00119	0.00257	CcSEcCtD
Bortezomib—CYP1A2—liver—hepatitis B	0.00118	0.00725	CbGeAlD
Bortezomib—Ill-defined disorder—Telbivudine—hepatitis B	0.00117	0.00253	CcSEcCtD
Bortezomib—Anorexia—Adefovir Dipivoxil—hepatitis B	0.00117	0.00252	CcSEcCtD
Bortezomib—Migraine—Lamivudine—hepatitis B	0.00116	0.00251	CcSEcCtD
Bortezomib—CYP1A1—liver—hepatitis B	0.00116	0.00715	CbGeAlD
Bortezomib—Malaise—Telbivudine—hepatitis B	0.00114	0.00246	CcSEcCtD
Bortezomib—Insomnia—Entecavir—hepatitis B	0.00113	0.00245	CcSEcCtD
Bortezomib—CYP2C9—liver—hepatitis B	0.00112	0.00688	CbGeAlD
Bortezomib—Musculoskeletal discomfort—Adefovir Dipivoxil—hepatitis B	0.00111	0.00241	CcSEcCtD
Bortezomib—Dyspepsia—Entecavir—hepatitis B	0.0011	0.00239	CcSEcCtD
Bortezomib—Cough—Telbivudine—hepatitis B	0.0011	0.00238	CcSEcCtD
Bortezomib—Dehydration—Lamivudine—hepatitis B	0.0011	0.00238	CcSEcCtD
Bortezomib—CYP3A4—blood—hepatitis B	0.00109	0.00671	CbGeAlD
Bortezomib—Gastrointestinal disorder—Entecavir—hepatitis B	0.00108	0.00234	CcSEcCtD
Bortezomib—Fatigue—Entecavir—hepatitis B	0.00108	0.00234	CcSEcCtD
Bortezomib—Abdominal pain upper—Lamivudine—hepatitis B	0.00108	0.00233	CcSEcCtD
Bortezomib—Dyspepsia—Adefovir Dipivoxil—hepatitis B	0.00108	0.00233	CcSEcCtD
Bortezomib—Arthralgia—Telbivudine—hepatitis B	0.00107	0.00232	CcSEcCtD
Bortezomib—Chest pain—Telbivudine—hepatitis B	0.00107	0.00232	CcSEcCtD
Bortezomib—Myalgia—Telbivudine—hepatitis B	0.00107	0.00232	CcSEcCtD
Bortezomib—CYP2D6—blood—hepatitis B	0.00107	0.0066	CbGeAlD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Telbivudine—hepatitis B	0.00107	0.00231	CcSEcCtD
Bortezomib—Cramp muscle—Lamivudine—hepatitis B	0.00106	0.0023	CcSEcCtD
Bortezomib—Decreased appetite—Adefovir Dipivoxil—hepatitis B	0.00106	0.0023	CcSEcCtD
Bortezomib—Discomfort—Telbivudine—hepatitis B	0.00106	0.0023	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Adefovir Dipivoxil—hepatitis B	0.00106	0.00228	CcSEcCtD
Bortezomib—Nasopharyngitis—Lamivudine—hepatitis B	0.00106	0.00228	CcSEcCtD
Bortezomib—Muscular weakness—Lamivudine—hepatitis B	0.00104	0.00225	CcSEcCtD
Bortezomib—Abdominal distension—Lamivudine—hepatitis B	0.00103	0.00222	CcSEcCtD
Bortezomib—Gastrointestinal pain—Entecavir—hepatitis B	0.00103	0.00222	CcSEcCtD
Bortezomib—Dysphagia—Lamivudine—hepatitis B	0.00102	0.00221	CcSEcCtD
Bortezomib—Influenza—Lamivudine—hepatitis B	0.00102	0.00221	CcSEcCtD
Bortezomib—Nervous system disorder—Telbivudine—hepatitis B	0.00101	0.00218	CcSEcCtD
Bortezomib—Thrombocytopenia—Telbivudine—hepatitis B	0.00101	0.00218	CcSEcCtD
Bortezomib—Pancreatitis—Lamivudine—hepatitis B	0.001	0.00216	CcSEcCtD
Bortezomib—Skin disorder—Telbivudine—hepatitis B	0.001	0.00216	CcSEcCtD
Bortezomib—Gastrointestinal pain—Adefovir Dipivoxil—hepatitis B	0.001	0.00216	CcSEcCtD
Bortezomib—Abdominal pain—Entecavir—hepatitis B	0.000991	0.00214	CcSEcCtD
Bortezomib—Body temperature increased—Entecavir—hepatitis B	0.000991	0.00214	CcSEcCtD
Bortezomib—Bronchitis—Lamivudine—hepatitis B	0.000981	0.00212	CcSEcCtD
Bortezomib—Abdominal discomfort—Lamivudine—hepatitis B	0.000978	0.00212	CcSEcCtD
Bortezomib—Pancytopenia—Lamivudine—hepatitis B	0.000969	0.0021	CcSEcCtD
Bortezomib—Abdominal pain—Adefovir Dipivoxil—hepatitis B	0.000967	0.00209	CcSEcCtD
Bortezomib—Body temperature increased—Adefovir Dipivoxil—hepatitis B	0.000967	0.00209	CcSEcCtD
Bortezomib—Neutropenia—Lamivudine—hepatitis B	0.000954	0.00206	CcSEcCtD
Bortezomib—Pollakiuria—Lamivudine—hepatitis B	0.000943	0.00204	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Telbivudine—hepatitis B	0.000938	0.00203	CcSEcCtD
Bortezomib—Insomnia—Telbivudine—hepatitis B	0.000931	0.00202	CcSEcCtD
Bortezomib—Paraesthesia—Telbivudine—hepatitis B	0.000925	0.002	CcSEcCtD
Bortezomib—Hyperglycaemia—Lamivudine—hepatitis B	0.000921	0.00199	CcSEcCtD
Bortezomib—Dyspepsia—Telbivudine—hepatitis B	0.000906	0.00196	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Lamivudine—hepatitis B	0.000902	0.00195	CcSEcCtD
Bortezomib—Asthenia—Entecavir—hepatitis B	0.000899	0.00195	CcSEcCtD
Bortezomib—Renal failure—Lamivudine—hepatitis B	0.000894	0.00194	CcSEcCtD
Bortezomib—Neuropathy peripheral—Lamivudine—hepatitis B	0.000892	0.00193	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Telbivudine—hepatitis B	0.000889	0.00192	CcSEcCtD
Bortezomib—Fatigue—Telbivudine—hepatitis B	0.000888	0.00192	CcSEcCtD
Bortezomib—Stomatitis—Lamivudine—hepatitis B	0.000887	0.00192	CcSEcCtD
Bortezomib—Pain—Telbivudine—hepatitis B	0.000881	0.00191	CcSEcCtD
Bortezomib—Asthenia—Adefovir Dipivoxil—hepatitis B	0.000877	0.0019	CcSEcCtD
Bortezomib—Pruritus—Adefovir Dipivoxil—hepatitis B	0.000865	0.00187	CcSEcCtD
Bortezomib—Hepatobiliary disease—Lamivudine—hepatitis B	0.000861	0.00186	CcSEcCtD
Bortezomib—Epistaxis—Lamivudine—hepatitis B	0.000858	0.00186	CcSEcCtD
Bortezomib—Diarrhoea—Entecavir—hepatitis B	0.000858	0.00186	CcSEcCtD
Bortezomib—Sinusitis—Lamivudine—hepatitis B	0.000854	0.00185	CcSEcCtD
Bortezomib—CYP3A4—liver—hepatitis B	0.000852	0.00524	CbGeAlD
Bortezomib—Feeling abnormal—Telbivudine—hepatitis B	0.000849	0.00184	CcSEcCtD
Bortezomib—Gastrointestinal pain—Telbivudine—hepatitis B	0.000842	0.00182	CcSEcCtD
Bortezomib—CYP2D6—liver—hepatitis B	0.000838	0.00516	CbGeAlD
Bortezomib—Diarrhoea—Adefovir Dipivoxil—hepatitis B	0.000837	0.00181	CcSEcCtD
Bortezomib—Dizziness—Entecavir—hepatitis B	0.000829	0.00179	CcSEcCtD
Bortezomib—Hepatitis—Lamivudine—hepatitis B	0.000817	0.00177	CcSEcCtD
Bortezomib—Body temperature increased—Telbivudine—hepatitis B	0.000814	0.00176	CcSEcCtD
Bortezomib—Abdominal pain—Telbivudine—hepatitis B	0.000814	0.00176	CcSEcCtD
Bortezomib—Hypoaesthesia—Lamivudine—hepatitis B	0.000813	0.00176	CcSEcCtD
Bortezomib—Connective tissue disorder—Lamivudine—hepatitis B	0.000803	0.00174	CcSEcCtD
Bortezomib—Vomiting—Entecavir—hepatitis B	0.000797	0.00172	CcSEcCtD
Bortezomib—Rash—Entecavir—hepatitis B	0.00079	0.00171	CcSEcCtD
Bortezomib—Dermatitis—Entecavir—hepatitis B	0.00079	0.00171	CcSEcCtD
Bortezomib—Headache—Entecavir—hepatitis B	0.000785	0.0017	CcSEcCtD
Bortezomib—Vomiting—Adefovir Dipivoxil—hepatitis B	0.000778	0.00168	CcSEcCtD
Bortezomib—Erythema multiforme—Lamivudine—hepatitis B	0.000772	0.00167	CcSEcCtD
Bortezomib—Rash—Adefovir Dipivoxil—hepatitis B	0.000771	0.00167	CcSEcCtD
Bortezomib—Dermatitis—Adefovir Dipivoxil—hepatitis B	0.00077	0.00167	CcSEcCtD
Bortezomib—Headache—Adefovir Dipivoxil—hepatitis B	0.000766	0.00166	CcSEcCtD
Bortezomib—Nausea—Entecavir—hepatitis B	0.000745	0.00161	CcSEcCtD
Bortezomib—Asthenia—Telbivudine—hepatitis B	0.000739	0.0016	CcSEcCtD
Bortezomib—Immune system disorder—Lamivudine—hepatitis B	0.000738	0.0016	CcSEcCtD
Bortezomib—Mediastinal disorder—Lamivudine—hepatitis B	0.000736	0.00159	CcSEcCtD
Bortezomib—Chills—Lamivudine—hepatitis B	0.000733	0.00159	CcSEcCtD
Bortezomib—Pruritus—Telbivudine—hepatitis B	0.000729	0.00158	CcSEcCtD
Bortezomib—Nausea—Adefovir Dipivoxil—hepatitis B	0.000726	0.00157	CcSEcCtD
Bortezomib—Erythema—Lamivudine—hepatitis B	0.000711	0.00154	CcSEcCtD
Bortezomib—Malnutrition—Lamivudine—hepatitis B	0.000711	0.00154	CcSEcCtD
Bortezomib—Diarrhoea—Telbivudine—hepatitis B	0.000705	0.00152	CcSEcCtD
Bortezomib—Flatulence—Lamivudine—hepatitis B	0.000701	0.00152	CcSEcCtD
Bortezomib—Dysgeusia—Lamivudine—hepatitis B	0.000696	0.00151	CcSEcCtD
Bortezomib—Back pain—Lamivudine—hepatitis B	0.000688	0.00149	CcSEcCtD
Bortezomib—Muscle spasms—Lamivudine—hepatitis B	0.000684	0.00148	CcSEcCtD
Bortezomib—Dizziness—Telbivudine—hepatitis B	0.000681	0.00147	CcSEcCtD
Bortezomib—Tremor—Lamivudine—hepatitis B	0.000666	0.00144	CcSEcCtD
Bortezomib—Ill-defined disorder—Lamivudine—hepatitis B	0.00066	0.00143	CcSEcCtD
Bortezomib—Anaemia—Lamivudine—hepatitis B	0.000657	0.00142	CcSEcCtD
Bortezomib—Vomiting—Telbivudine—hepatitis B	0.000655	0.00142	CcSEcCtD
Bortezomib—Angioedema—Lamivudine—hepatitis B	0.00065	0.00141	CcSEcCtD
Bortezomib—Rash—Telbivudine—hepatitis B	0.000649	0.0014	CcSEcCtD
Bortezomib—Dermatitis—Telbivudine—hepatitis B	0.000649	0.0014	CcSEcCtD
Bortezomib—Headache—Telbivudine—hepatitis B	0.000645	0.0014	CcSEcCtD
Bortezomib—Malaise—Lamivudine—hepatitis B	0.000641	0.00139	CcSEcCtD
Bortezomib—Vertigo—Lamivudine—hepatitis B	0.000639	0.00138	CcSEcCtD
Bortezomib—Syncope—Lamivudine—hepatitis B	0.000638	0.00138	CcSEcCtD
Bortezomib—Leukopenia—Lamivudine—hepatitis B	0.000636	0.00138	CcSEcCtD
Bortezomib—Loss of consciousness—Lamivudine—hepatitis B	0.000625	0.00135	CcSEcCtD
Bortezomib—Cough—Lamivudine—hepatitis B	0.00062	0.00134	CcSEcCtD
Bortezomib—Convulsion—Lamivudine—hepatitis B	0.000616	0.00133	CcSEcCtD
Bortezomib—Nausea—Telbivudine—hepatitis B	0.000612	0.00132	CcSEcCtD
Bortezomib—Chest pain—Lamivudine—hepatitis B	0.000605	0.00131	CcSEcCtD
Bortezomib—Arthralgia—Lamivudine—hepatitis B	0.000605	0.00131	CcSEcCtD
Bortezomib—Myalgia—Lamivudine—hepatitis B	0.000605	0.00131	CcSEcCtD
Bortezomib—Anxiety—Lamivudine—hepatitis B	0.000603	0.00131	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—hepatitis B	0.000601	0.0013	CcSEcCtD
Bortezomib—Discomfort—Lamivudine—hepatitis B	0.000598	0.00129	CcSEcCtD
Bortezomib—Confusional state—Lamivudine—hepatitis B	0.000585	0.00127	CcSEcCtD
Bortezomib—Oedema—Lamivudine—hepatitis B	0.00058	0.00126	CcSEcCtD
Bortezomib—Anaphylactic shock—Lamivudine—hepatitis B	0.00058	0.00126	CcSEcCtD
Bortezomib—Infection—Lamivudine—hepatitis B	0.000577	0.00125	CcSEcCtD
Bortezomib—Shock—Lamivudine—hepatitis B	0.000571	0.00124	CcSEcCtD
Bortezomib—Nervous system disorder—Lamivudine—hepatitis B	0.000569	0.00123	CcSEcCtD
Bortezomib—Thrombocytopenia—Lamivudine—hepatitis B	0.000568	0.00123	CcSEcCtD
Bortezomib—Skin disorder—Lamivudine—hepatitis B	0.000564	0.00122	CcSEcCtD
Bortezomib—Hyperhidrosis—Lamivudine—hepatitis B	0.000561	0.00121	CcSEcCtD
Bortezomib—Anorexia—Lamivudine—hepatitis B	0.000553	0.0012	CcSEcCtD
Bortezomib—Hypotension—Lamivudine—hepatitis B	0.000542	0.00117	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Lamivudine—hepatitis B	0.000529	0.00114	CcSEcCtD
Bortezomib—Insomnia—Lamivudine—hepatitis B	0.000525	0.00114	CcSEcCtD
Bortezomib—Paraesthesia—Lamivudine—hepatitis B	0.000521	0.00113	CcSEcCtD
Bortezomib—Dyspnoea—Lamivudine—hepatitis B	0.000517	0.00112	CcSEcCtD
Bortezomib—Dyspepsia—Lamivudine—hepatitis B	0.000511	0.00111	CcSEcCtD
Bortezomib—Decreased appetite—Lamivudine—hepatitis B	0.000504	0.00109	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Lamivudine—hepatitis B	0.000501	0.00108	CcSEcCtD
Bortezomib—Fatigue—Lamivudine—hepatitis B	0.0005	0.00108	CcSEcCtD
Bortezomib—Constipation—Lamivudine—hepatitis B	0.000496	0.00107	CcSEcCtD
Bortezomib—Pain—Lamivudine—hepatitis B	0.000496	0.00107	CcSEcCtD
Bortezomib—Feeling abnormal—Lamivudine—hepatitis B	0.000478	0.00103	CcSEcCtD
Bortezomib—Gastrointestinal pain—Lamivudine—hepatitis B	0.000475	0.00103	CcSEcCtD
Bortezomib—Urticaria—Lamivudine—hepatitis B	0.000461	0.000997	CcSEcCtD
Bortezomib—Abdominal pain—Lamivudine—hepatitis B	0.000459	0.000993	CcSEcCtD
Bortezomib—Body temperature increased—Lamivudine—hepatitis B	0.000459	0.000993	CcSEcCtD
Bortezomib—Hypersensitivity—Lamivudine—hepatitis B	0.000428	0.000925	CcSEcCtD
Bortezomib—Asthenia—Lamivudine—hepatitis B	0.000416	0.000901	CcSEcCtD
Bortezomib—Pruritus—Lamivudine—hepatitis B	0.000411	0.000888	CcSEcCtD
Bortezomib—Diarrhoea—Lamivudine—hepatitis B	0.000397	0.000859	CcSEcCtD
Bortezomib—Dizziness—Lamivudine—hepatitis B	0.000384	0.00083	CcSEcCtD
Bortezomib—Vomiting—Lamivudine—hepatitis B	0.000369	0.000798	CcSEcCtD
Bortezomib—Rash—Lamivudine—hepatitis B	0.000366	0.000792	CcSEcCtD
Bortezomib—Dermatitis—Lamivudine—hepatitis B	0.000366	0.000791	CcSEcCtD
Bortezomib—Headache—Lamivudine—hepatitis B	0.000364	0.000787	CcSEcCtD
Bortezomib—Nausea—Lamivudine—hepatitis B	0.000345	0.000746	CcSEcCtD
Bortezomib—PSMA1—Immune System—IL2—hepatitis B	5.8e-05	0.000155	CbGpPWpGaD
Bortezomib—PSMD1—Disease—CD4—hepatitis B	5.79e-05	0.000154	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL2—hepatitis B	5.77e-05	0.000154	CbGpPWpGaD
Bortezomib—PSMD2—Disease—CD4—hepatitis B	5.77e-05	0.000154	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL2—hepatitis B	5.75e-05	0.000153	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GGT2—hepatitis B	5.63e-05	0.00015	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CTNNB1—hepatitis B	5.6e-05	0.000149	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CTNNB1—hepatitis B	5.57e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—F2—hepatitis B	5.57e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CTNNB1—hepatitis B	5.55e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—F2—hepatitis B	5.54e-05	0.000148	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—ALB—hepatitis B	5.53e-05	0.000147	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—F2—hepatitis B	5.52e-05	0.000147	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—ALB—hepatitis B	5.5e-05	0.000147	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—ALB—hepatitis B	5.48e-05	0.000146	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CDKN1A—hepatitis B	5.47e-05	0.000146	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—PTEN—hepatitis B	5.46e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CDKN1A—hepatitis B	5.44e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—PTEN—hepatitis B	5.43e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—NFKB1—hepatitis B	5.43e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CDKN1A—hepatitis B	5.42e-05	0.000144	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—PTEN—hepatitis B	5.41e-05	0.000144	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—NFKB1—hepatitis B	5.41e-05	0.000144	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—NFKB1—hepatitis B	5.38e-05	0.000143	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	5.33e-05	0.000142	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CYP2A6—hepatitis B	5.28e-05	0.000141	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKR1B1—hepatitis B	5.24e-05	0.00014	CbGpPWpGaD
Bortezomib—PSMA1—Disease—CTNNB1—hepatitis B	5.17e-05	0.000138	CbGpPWpGaD
Bortezomib—PSMD1—Disease—CTNNB1—hepatitis B	5.15e-05	0.000137	CbGpPWpGaD
Bortezomib—PSMD2—Disease—CTNNB1—hepatitis B	5.12e-05	0.000136	CbGpPWpGaD
Bortezomib—PSMB5—Cell Cycle—TP53—hepatitis B	5.08e-05	0.000135	CbGpPWpGaD
Bortezomib—PSMB1—Cell Cycle—TP53—hepatitis B	5.08e-05	0.000135	CbGpPWpGaD
Bortezomib—PSMB2—Cell Cycle—TP53—hepatitis B	5.08e-05	0.000135	CbGpPWpGaD
Bortezomib—PSMA1—Disease—CDKN1A—hepatitis B	5.05e-05	0.000135	CbGpPWpGaD
Bortezomib—PSMA1—Disease—PTEN—hepatitis B	5.04e-05	0.000134	CbGpPWpGaD
Bortezomib—PSMD1—Disease—CDKN1A—hepatitis B	5.03e-05	0.000134	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GGT2—hepatitis B	5.02e-05	0.000134	CbGpPWpGaD
Bortezomib—PSMD1—Disease—PTEN—hepatitis B	5.02e-05	0.000134	CbGpPWpGaD
Bortezomib—PSMB8—Cell Cycle—TP53—hepatitis B	5.01e-05	0.000133	CbGpPWpGaD
Bortezomib—PSMD2—Disease—CDKN1A—hepatitis B	5e-05	0.000133	CbGpPWpGaD
Bortezomib—PSMD2—Disease—PTEN—hepatitis B	4.99e-05	0.000133	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IFNG—hepatitis B	4.95e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IFNG—hepatitis B	4.95e-05	0.000132	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IFNG—hepatitis B	4.95e-05	0.000132	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—ALB—hepatitis B	4.92e-05	0.000131	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCR5—hepatitis B	4.92e-05	0.000131	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCR5—hepatitis B	4.92e-05	0.000131	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCR5—hepatitis B	4.92e-05	0.000131	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IFNG—hepatitis B	4.88e-05	0.00013	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	4.86e-05	0.00013	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCR5—hepatitis B	4.85e-05	0.000129	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKR1B1—hepatitis B	4.82e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD4—hepatitis B	4.78e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD4—hepatitis B	4.78e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD4—hepatitis B	4.78e-05	0.000127	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKR1B1—hepatitis B	4.78e-05	0.000127	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GOT2—hepatitis B	4.77e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD4—hepatitis B	4.71e-05	0.000125	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GGT2—hepatitis B	4.62e-05	0.000123	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GGT2—hepatitis B	4.58e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CD4—hepatitis B	4.41e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CD4—hepatitis B	4.41e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB1—Disease—CD4—hepatitis B	4.41e-05	0.000118	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL2—hepatitis B	4.4e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL2—hepatitis B	4.4e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL2—hepatitis B	4.4e-05	0.000117	CbGpPWpGaD
Bortezomib—PSMB8—Disease—CD4—hepatitis B	4.35e-05	0.000116	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL2—hepatitis B	4.33e-05	0.000115	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CTNNB1—hepatitis B	4.24e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CTNNB1—hepatitis B	4.24e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CTNNB1—hepatitis B	4.24e-05	0.000113	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—F2—hepatitis B	4.22e-05	0.000112	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—F2—hepatitis B	4.22e-05	0.000112	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—F2—hepatitis B	4.22e-05	0.000112	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—PTEN—hepatitis B	4.22e-05	0.000112	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PTEN—hepatitis B	4.2e-05	0.000112	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—ALB—hepatitis B	4.19e-05	0.000112	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—ALB—hepatitis B	4.19e-05	0.000112	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—ALB—hepatitis B	4.19e-05	0.000112	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CTNNB1—hepatitis B	4.18e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PTEN—hepatitis B	4.18e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMA1—Disease—TGFB1—hepatitis B	4.18e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—F2—hepatitis B	4.16e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMD1—Disease—TGFB1—hepatitis B	4.16e-05	0.000111	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	4.16e-05	0.000111	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CDKN1A—hepatitis B	4.15e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CDKN1A—hepatitis B	4.15e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CDKN1A—hepatitis B	4.15e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMD2—Disease—TGFB1—hepatitis B	4.14e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—PTEN—hepatitis B	4.14e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—PTEN—hepatitis B	4.14e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—PTEN—hepatitis B	4.14e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—ALB—hepatitis B	4.13e-05	0.00011	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GOT1—hepatitis B	4.12e-05	0.00011	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—GGT1—hepatitis B	4.12e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—NFKB1—hepatitis B	4.12e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—NFKB1—hepatitis B	4.12e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—NFKB1—hepatitis B	4.12e-05	0.00011	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CDKN1A—hepatitis B	4.09e-05	0.000109	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKR1B1—hepatitis B	4.08e-05	0.000109	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—PTEN—hepatitis B	4.08e-05	0.000109	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—NFKB1—hepatitis B	4.06e-05	0.000108	CbGpPWpGaD
Bortezomib—PSMB1—Disease—CTNNB1—hepatitis B	3.92e-05	0.000104	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CTNNB1—hepatitis B	3.92e-05	0.000104	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CTNNB1—hepatitis B	3.92e-05	0.000104	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GGT2—hepatitis B	3.91e-05	0.000104	CbGpPWpGaD
Bortezomib—PSMB8—Disease—CTNNB1—hepatitis B	3.86e-05	0.000103	CbGpPWpGaD
Bortezomib—PSMB1—Disease—CDKN1A—hepatitis B	3.83e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CDKN1A—hepatitis B	3.83e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CDKN1A—hepatitis B	3.83e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PTEN—hepatitis B	3.82e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PTEN—hepatitis B	3.82e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PTEN—hepatitis B	3.82e-05	0.000102	CbGpPWpGaD
Bortezomib—PSMB8—Disease—CDKN1A—hepatitis B	3.77e-05	0.000101	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PTEN—hepatitis B	3.77e-05	0.0001	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	3.75e-05	0.0001	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL2—hepatitis B	3.75e-05	9.99e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL2—hepatitis B	3.73e-05	9.94e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CYP2A6—hepatitis B	3.72e-05	9.9e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL2—hepatitis B	3.71e-05	9.9e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CTNNB1—hepatitis B	3.62e-05	9.64e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CTNNB1—hepatitis B	3.6e-05	9.6e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CTNNB1—hepatitis B	3.59e-05	9.55e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—CDKN1A—hepatitis B	3.54e-05	9.42e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—PTEN—hepatitis B	3.53e-05	9.4e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CDKN1A—hepatitis B	3.52e-05	9.38e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PTEN—hepatitis B	3.51e-05	9.35e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NFKB1—hepatitis B	3.51e-05	9.35e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CDKN1A—hepatitis B	3.5e-05	9.33e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PTEN—hepatitis B	3.5e-05	9.31e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—NFKB1—hepatitis B	3.5e-05	9.31e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NFKB1—hepatitis B	3.48e-05	9.27e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—ALB—hepatitis B	3.47e-05	9.24e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IL6—hepatitis B	3.41e-05	9.08e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP2A6—hepatitis B	3.41e-05	9.08e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL6—hepatitis B	3.39e-05	9.04e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL6—hepatitis B	3.38e-05	9e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GOT2—hepatitis B	3.36e-05	8.96e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PTEN—hepatitis B	3.2e-05	8.52e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PTEN—hepatitis B	3.2e-05	8.52e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PTEN—hepatitis B	3.2e-05	8.52e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—hepatitis B	3.18e-05	8.47e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TGFB1—hepatitis B	3.17e-05	8.43e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TGFB1—hepatitis B	3.17e-05	8.43e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TGFB1—hepatitis B	3.17e-05	8.43e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PTEN—hepatitis B	3.15e-05	8.4e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKR1B1—hepatitis B	3.15e-05	8.39e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—IL6—hepatitis B	3.15e-05	8.39e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—IL6—hepatitis B	3.13e-05	8.34e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TGFB1—hepatitis B	3.12e-05	8.31e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—IL6—hepatitis B	3.12e-05	8.31e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GOT2—hepatitis B	3.08e-05	8.21e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP2A6—hepatitis B	3.04e-05	8.11e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GGT2—hepatitis B	3.02e-05	8.04e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TGFB1—hepatitis B	2.93e-05	7.79e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TGFB1—hepatitis B	2.91e-05	7.76e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GGT1—hepatitis B	2.9e-05	7.73e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—GOT1—hepatitis B	2.9e-05	7.73e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TGFB1—hepatitis B	2.9e-05	7.72e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL2—hepatitis B	2.84e-05	7.57e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL2—hepatitis B	2.84e-05	7.57e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL2—hepatitis B	2.84e-05	7.57e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—ALB—hepatitis B	2.84e-05	7.56e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL2—hepatitis B	2.8e-05	7.46e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP2A6—hepatitis B	2.8e-05	7.45e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP2A6—hepatitis B	2.77e-05	7.39e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GOT2—hepatitis B	2.75e-05	7.33e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CTNNB1—hepatitis B	2.74e-05	7.31e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CTNNB1—hepatitis B	2.74e-05	7.31e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CTNNB1—hepatitis B	2.74e-05	7.31e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CTNNB1—hepatitis B	2.71e-05	7.21e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CDKN1A—hepatitis B	2.68e-05	7.14e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CDKN1A—hepatitis B	2.68e-05	7.14e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CDKN1A—hepatitis B	2.68e-05	7.14e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PTEN—hepatitis B	2.67e-05	7.12e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PTEN—hepatitis B	2.67e-05	7.12e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PTEN—hepatitis B	2.67e-05	7.12e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NFKB1—hepatitis B	2.66e-05	7.09e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NFKB1—hepatitis B	2.66e-05	7.09e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NFKB1—hepatitis B	2.66e-05	7.09e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GOT1—hepatitis B	2.66e-05	7.09e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—GGT1—hepatitis B	2.66e-05	7.09e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	2.65e-05	7.05e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CDKN1A—hepatitis B	2.64e-05	7.04e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PTEN—hepatitis B	2.64e-05	7.02e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NFKB1—hepatitis B	2.62e-05	6.99e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—hepatitis B	2.59e-05	6.89e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL6—hepatitis B	2.58e-05	6.88e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL6—hepatitis B	2.58e-05	6.88e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL6—hepatitis B	2.58e-05	6.88e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL6—hepatitis B	2.55e-05	6.79e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GOT2—hepatitis B	2.53e-05	6.74e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GOT2—hepatitis B	2.51e-05	6.68e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	2.43e-05	6.46e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—hepatitis B	2.41e-05	6.41e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—hepatitis B	2.4e-05	6.38e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—IL6—hepatitis B	2.39e-05	6.35e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—IL6—hepatitis B	2.39e-05	6.35e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—IL6—hepatitis B	2.39e-05	6.35e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—hepatitis B	2.39e-05	6.35e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GGT1—hepatitis B	2.38e-05	6.33e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—GOT1—hepatitis B	2.38e-05	6.33e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP2A6—hepatitis B	2.37e-05	6.32e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—IL6—hepatitis B	2.35e-05	6.27e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—hepatitis B	2.22e-05	5.91e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—hepatitis B	2.22e-05	5.91e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—hepatitis B	2.22e-05	5.91e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hepatitis B	2.21e-05	5.89e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—IL6—hepatitis B	2.2e-05	5.87e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—IL6—hepatitis B	2.19e-05	5.84e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—ALB—hepatitis B	2.19e-05	5.84e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—hepatitis B	2.19e-05	5.82e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GOT1—hepatitis B	2.18e-05	5.82e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—GGT1—hepatitis B	2.18e-05	5.82e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—IL6—hepatitis B	2.18e-05	5.82e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GOT1—hepatitis B	2.17e-05	5.77e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—GGT1—hepatitis B	2.17e-05	5.77e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	2.16e-05	5.77e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GOT2—hepatitis B	2.14e-05	5.71e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	1.97e-05	5.26e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GGT1—hepatitis B	1.85e-05	4.93e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—GOT1—hepatitis B	1.85e-05	4.93e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP2A6—hepatitis B	1.83e-05	4.87e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—hepatitis B	1.83e-05	4.86e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—hepatitis B	1.83e-05	4.86e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—hepatitis B	1.83e-05	4.86e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—hepatitis B	1.8e-05	4.79e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	1.69e-05	4.49e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTEN—hepatitis B	1.67e-05	4.45e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—IL6—hepatitis B	1.67e-05	4.45e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—IL6—hepatitis B	1.67e-05	4.45e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—IL6—hepatitis B	1.67e-05	4.45e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GOT2—hepatitis B	1.65e-05	4.41e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—IL6—hepatitis B	1.65e-05	4.39e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—ALB—hepatitis B	1.54e-05	4.11e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GOT1—hepatitis B	1.43e-05	3.8e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—GGT1—hepatitis B	1.43e-05	3.8e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—ALB—hepatitis B	1.42e-05	3.77e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—ALB—hepatitis B	1.26e-05	3.37e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTEN—hepatitis B	1.18e-05	3.14e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—ALB—hepatitis B	1.16e-05	3.1e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—ALB—hepatitis B	1.15e-05	3.07e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTEN—hepatitis B	1.08e-05	2.88e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—ALB—hepatitis B	9.84e-06	2.62e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTEN—hepatitis B	9.64e-06	2.57e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTEN—hepatitis B	8.87e-06	2.36e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTEN—hepatitis B	8.79e-06	2.34e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—ALB—hepatitis B	7.6e-06	2.02e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTEN—hepatitis B	7.51e-06	2e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTEN—hepatitis B	5.8e-06	1.54e-05	CbGpPWpGaD
